Post hoc analysis of the MISTRAL trial in 244 patients with advanced pancreatic cancer: corticosteroid use was associated with greater weight loss (on average 1.48% more per month) and poorer appetite at every time point; higher symptom burden may partly explain this.
Secondary analysisn = 244
Goodrose-Flores et al. Associations of corticosteroid therapy with weight change and appetite in patients with advanced pancreatic cancer - a post hoc analysis from the MISTRAL trial